<DOC>
	<DOCNO>NCT02242695</DOCNO>
	<brief_summary>A clinical study compare clinical efficacy vaginal tablet contain 10mg dequalinium chloride ( Fluomizin ) clinical efficacy 100mg clotrimazole patient suffer vulvovaginal candidiasis , assess safety two medication treatment , evaluate woman 's satisfaction two treatment .</brief_summary>
	<brief_title>Comparative Efficacy Study 10 mg Dequalinium Chloride ( Fluomizin ) Treatment Vulvovaginal Candidiasis</brief_title>
	<detailed_description />
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidiasis , Vulvovaginal</mesh_term>
	<mesh_term>Clotrimazole</mesh_term>
	<mesh_term>Dequalinium</mesh_term>
	<mesh_term>Miconazole</mesh_term>
	<criteria>Clinical sign symptom vulvovaginal candididiasis Total Severity Score , Total Severity Score least 4 ( 015 : vaginal itching ( 03 ) , vaginal burning soreness ( 03 ) , abnormal vaginal discharge ( 03 ) , vulvo/vaginal erythema edema ( 03 ) , vulvar excoriation fissure formation ( 03 ) . Direct microscopy ( Wet smear ) positive yeast form ( hyphae/pseudohyphae ) budding yeast . normal vaginal pH ( high 4.5 ) baseline . Women age 18 45 year old . Women comply clinical trial instruction , return followup visit . Signed Written Informed Consent participate study . Recurrent vulvovaginal candidiasis ( 4 episode VVC last 12 month ) . Women cause vaginal infection , e.g . bacterial vaginosis , aerobic vaginitis , trichomoniasis , mixed infection Women use oral vaginal antifungal within 2 week prior enrolment study . Women use intravaginal product , also vaginal douche contain soap anionic , surfaceactive substance , within 2 week prior enrolment study . Women use antibiotic antiinfective within 2 week prior enrolment . Cervicitis , abnormal PAP smear last 6 month . Severe systemic disease ( HIV infection , diabetes mellitus , cancer , tuberculosis , autoimmune disease , severe psychiatric condition , etc. ) . Women confirm Neisseria gonorrhoea Chlamydia trachomatis . Women menstruation bleed enrolment . Known suspected hypersensitivity one study medication , inclusive excipients . Participation patient another investigational drug study concomitantly within 30 day prior entry study . Patient relative , staff directly reporting , investigator .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>vulvovaginal candidiasis</keyword>
	<keyword>vulvovaginal candidosis</keyword>
	<keyword>mycotic vaginal infection</keyword>
	<keyword>dequalinium chloride</keyword>
	<keyword>Fluomizin</keyword>
	<keyword>clotrimazole</keyword>
	<keyword>canesten</keyword>
</DOC>